Acrivon Therapeutics
ACRV
ACRV
55 hedge funds and large institutions have $161M invested in Acrivon Therapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
1.81% less ownership
Funds ownership: 75.99% → 74.18% (-1.8%)
Holders
55
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$1.37M | |
| 2 | +$920K | |
| 3 | +$372K | |
| 4 |
Millennium Management
New York
|
+$313K |
| 5 |
PCM
Prelude Capital Management
New York
|
+$297K |
Top Sellers
| 1 | -$3.83M | |
| 2 | -$1.1M | |
| 3 | -$851K | |
| 4 |
Charles Schwab
San Francisco,
California
|
-$218K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$205K |